FORM 3
        
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL
OMB Number: 3235-0104
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Harms Thomas

2. Date of Event Requiring Statement (MM/DD/YYYY)
8/1/2017 

3. Issuer Name and Ticker or Trading Symbol

HERBALIFE LTD. [HLF]

(Last)        (First)        (Middle)

800 W. OLYMPIC BLVD., SUITE 406

4. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                            _____ 10% Owner
___ X ___ Officer (give title below)          _____ Other (specify below)
SVP, China & APAC /

(Street)

LOS ANGELES, CA 90015       

(City)              (State)              (Zip)
5. If Amendment, Date Original Filed (MM/DD/YYYY)

 

6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person


Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)
2. Amount of Securities Beneficially Owned
(Instr. 4)
3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)
4. Nature of Indirect Beneficial Ownership
(Instr. 5)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 4)
2. Date Exercisable and Expiration Date
(MM/DD/YYYY)
3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)
4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)
6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Appreciation Right   2/28/2008   (1) 2/28/2018   Common Stock   1000   $21.57   D    
Stock Appreciation Right   2/27/2009   (2) 2/27/2019   Common Stock   6000   $6.82   D    
Stock Appreciation Right   2/27/2009   (3) 2/27/2019   Common Stock   15000   $6.82   D    
Stock Appreciation Right   5/7/2010   (4) 5/7/2020   Common Stock   5032   $22.94   D    
Stock Appreciation Right   5/18/2011   (5) 5/18/2021   Common Stock   4167   $53.29   D    
Stock Appreciation Right   3/1/2012   (6) 3/1/2022   Common Stock   3711   $67.70   D    
Stock Appreciation Right   5/31/2012   (7) 5/31/2022   Common Stock   11803   $44.79   D    
Stock Appreciation Right   12/19/2013   (8) 12/19/2023   Common Stock   5448   $79.58   D    
Stock Appreciation Right   4/30/2014   (9) 4/30/2024   Common Stock   6639   $59.98   D    
Stock Appreciation Right   3/2/2015   (10) 3/2/2025   Common Stock   9176   $30.44   D    
Stock Appreciation Right   5/9/2016   (11) 5/9/2026   Common Stock   3023   $62.51   D    
Stock Appreciation Right   2/27/2017   (12) 2/27/2027   Common Stock   3177   $57.19   D    

Explanation of Responses:
(1)  On February 28, 2008 the reporting person was granted 6,000 Stock Appreciation Right ("SARs"). These SARs were fully vested as of February 28, 2011.
(2)  On February 27, 2009 the reporting person was granted 6,000 SARs. These SARs were fully vested as of February 27, 2012.
(3)  On February 27, 2009 the reporting person was granted 15,000 SARs. These SARs were fully vested as of February 27, 2014.
(4)  On May 7, 2010 the reporting person was granted 5,032 SARs. These SARs were fully vested as of May 7, 2013.
(5)  On May 18, 2011, the reporting person was granted 4,167 SARs. These SARs were fully vested as of May 18, 2014.
(6)  On March 1, 2012, the reporting person was granted 3,711 SARs. These SARs were fully vested as of March 1, 2015.
(7)  On May 31, 2012, the reporting person was granted 11,803 SARs. These SARs were fully vested as of May 31, 2015.
(8)  On December 19, 2013, the reporting person was granted 5,448 SARs. These SARs were fully vested as of December 19, 2016.
(9)  On April 30, 2014, the reporting person was granted 6,639 SARs. These SARs were fully vested as of April 30, 2017.
(10)  On March 2, 2015, the reporting person was granted 9,176 SARs. Forty percent (40%) of these SARs were vested as of March 2, 2017, and the remaining sixty percent (60%) will vest on March 2, 2018.
(11)  On May 9, 2016, the reporting person was granted 3,023 SARs. Twenty percent (20%) of these SARs were vested as of May 9, 2017, twenty percent (20%) will vest on May 9, 2018, and the remaining sixty percent (60%) will vest on May 2, 2019.
(12)  On February 27, 2017, the reporting person was granted 3,177 SARs. Twenty percent (20%) of these SARs will vest on each of February 27, 2018 and February 27, 2019, and the remaining sixty percent (60%) will vest on February 27, 2020.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
Harms Thomas
800 W. OLYMPIC BLVD., SUITE 406
LOS ANGELES, CA 90015


SVP, China & APAC

Signatures
/s/ Eileen Uy, Attorney-in-Fact for Thomas Harms 8/4/2017
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Herbalife (NYSE:HLF)
過去 株価チャート
から 3 2024 まで 4 2024 Herbalifeのチャートをもっと見るにはこちらをクリック
Herbalife (NYSE:HLF)
過去 株価チャート
から 4 2023 まで 4 2024 Herbalifeのチャートをもっと見るにはこちらをクリック